Myopia News
-
BRIM Biotech submits US Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease to the FDA
BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration (FDA). If the FDA has no further comments after the 30-day review period, BRIM will proceed to initiate the Phase 3 clinical trial in December. Based on its ...
-
Bayer receives positive CHMP opinion for Eylea in the EU for treatment of preterm infants with retinopathy of prematurity
Recommendation is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness Bayer will apply for a patent term extension for the patent covering aflibercept, the active ingredient in Eylea™, of six months once the European Commission adopts a decision for a label extension ...
By Bayer AG
-
G8 Myopia: G8 Leaders Must Look Ahead for New Solutions Towards a 21st Century Green Economy and Not Backward Towards 20th Century Mistakes
During the G8 summit, the French Presidency is clearly trying to revive an old-style decision-making process. In its final declaration, the G8 adopted common positions related to energy, climate change and green growth. However, it keeps reaffirming previous political declarations without taking new commitments. The G8 position on green growth is far from being enough. No specific information is ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you